撰文丨王聪 编辑丨王多鱼 排版丨水成文 疼痛 是人们就医的首要原因，仅背痛一项就影响着全球超过 6 亿人。尽管存在使人成瘾的风险，阿片类药物在美国仍被广泛用于术后和严重疼痛的 治疗。鉴于阿片类药物使用障碍造成的巨大经济负担和社会影响，美国联邦医疗保健机构已将开发更安全的替代品列为优先事项。 在过去的三十年里，疼痛研究一直致力于靶向外周感觉神经元中的离子通道，尤其是电压门控钠通道 Nav1.7 和 Nav1.8。尽管这种方法已取得一些 成效，但鉴于中枢敏化在广泛性慢性疼痛中的作用，更有效的慢性疼痛治疗方法可能需要同时靶向 外周神经系统 （PNS） 和 中枢神经系统 （CNS） 。 G 蛋白偶联受体 （GPCR） 在外周神经系统 （PNS） 和中枢神经系统 （CNS） 中均有广泛表达，是药物作用靶点中最大的家族，其中包括镇痛药 物靶点。 2025 年 5 月 19 日，杜克大学医学中心 纪如荣 教授团队在国际顶尖学术期刊 Cell 上发表了题为： Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and ...

2025年1-4月回顾 截至2025年4月30日，沪深300指数累计下跌4.2%，保险Ⅱ(申万)下跌6.1%，跑输沪深300指数1.9pct。具 体看，A股新华保险-3.2%>中国人保-6.5%>中国太保-12.4%>中国人寿-13.4%，各家均下跌，仅新华和 平安跑赢沪深300指数。板块估值回调且表现弱于大盘，主要因2025年保险股面临较大的业绩高基数压 力，同时资产端长端利率下行、资产荒加剧等投资端核心压制因素仍在持续，负债端开门红新单销售不 及预期，保险股估值在去年修复到相对合理位置后，受以上利空因素影响回撤。 行业投资逻辑 保险公司盈利由承保利润和投资利润构成。承保利润受保费收入以及赔付和运营成本影响。投资利润取 决于投资收益和负债的利率成本，受资本市场、预定利率以及产品结构影响。该行认为保险行业2025下 半年将以资产负债结构调整优化为核心，演绎破局利差损困局的核心主线，若被验证将对重估保险配置 价值提供有力支撑。 智通财经APP获悉，兴业证券发布研报称，看好保险β配置机会，聚焦业绩确定性较强、资负匹配较优 以及业绩弹性较强标的。该行认为前期保险估值的回调已经充分反映当期利率下行以及后续业绩承压的 ...

CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will host an in-person key opinion leader (KOL) event, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, to discuss the e ...

Company Overview - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1][3] - The company's lead investigational drug, elraglusib, targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments, including several DNA Damage Response (DDR) pathways [3] Upcoming Events - Daniel Schmitt, President & CEO of Actuate, will present at the Citizens Life Sciences Conference 2025 on May 8, 2025, at 12:30 PM ET [1][2] - The presentation will be accessible via a webcast on the Actuate website, and the management team will participate in one-on-one investor meetings during the event [2]

Core Viewpoint - Bicara Therapeutics Inc. is advancing its lead product, ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, showing promising results in treating solid tumors, particularly in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma [1][2][9] Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with ficerafusp alfa as its lead program [9] - The company aims to address significant unmet needs in cancer treatment, particularly in patients with advanced or metastatic diseases [4][9] Product Development - Ficerafusp alfa is a first-in-class bifunctional antibody that combines an EGFR-directed monoclonal antibody with a TGF-β binding domain, potentially enhancing anti-tumor activity by targeting both cancer cell survival and immunosuppressive signaling [7][9] - The drug is currently being evaluated in pivotal Phase 2/3 clinical trials for first-line recurrent/metastatic head and neck squamous cell carcinoma [8] Clinical Data Highlights - Recent presentations at the AACR Annual Meeting 2025 showcased data supporting ficerafusp alfa's ability to block TGF-β signaling, which may prevent resistance mechanisms in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma [2][3] - In a Phase 1/1b trial for second-line metastatic cutaneous squamous cell carcinoma, ficerafusp alfa demonstrated an overall response rate of 30.4% and a clinical benefit rate of 82.6%, with a median progression-free survival of 7.0 months [3][4] - The drug also showed potential in reversing acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant lung cancer, indicating its broad therapeutic potential [5][11] Market Context - Cutaneous squamous cell carcinoma is the second most common skin cancer, with rising incidence highlighting the need for effective treatment options, especially for patients who progress on anti-PD-1 therapies [4][6] - The lack of approved second-line therapies for patients with advanced or metastatic cutaneous squamous cell carcinoma underscores the importance of ficerafusp alfa's development [4][6]

Core Insights - Pliant Therapeutics, Inc. announced promising interim results from its Phase 1 clinical trial of PLN-101095, showing a 50% objective response rate in patients with advanced or metastatic solid tumors who are refractory to immune checkpoint inhibitors [2][5][6] Group 1: Clinical Trial Details - The trial is evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab in patients with ICI-refractory tumors [2][7] - Three partial responses were observed in cohort three at the highest tested dose of 1000 mg administered orally twice daily [2][5] - The trial has enrolled nine patients across three cohorts, with treatment durations of 14 days followed by combination therapy [3][5] Group 2: Efficacy Observations - Among the six patients treated at the 1000 mg BID dose, three confirmed partial responses were noted, with significant reductions in tumor sizes: 74% for NSCLC, 48% for cholangiocarcinoma, and 42% for melanoma [5][6] - Initial partial responses were observed at Week 10 for NSCLC, Week 34 for cholangiocarcinoma, and Week 18 for melanoma [5] Group 3: Safety and Tolerability - PLN-101095 was generally well tolerated across all doses tested, indicating a favorable safety profile [2][5][6] - The ongoing trial is currently enrolling the fourth cohort, which will evaluate PLN-101095 at a different dosing schedule of 1000 mg three times daily [6] Group 4: Company Background - Pliant Therapeutics is focused on developing novel therapeutics for fibrotic diseases, with PLN-101095 being a key candidate for treating solid tumors [8] - The company has received regulatory designations for its lead product candidate, bexotegrast, indicating its commitment to advancing innovative treatments [8]

15 ult JE 相伴成长 CCB Principal Asset Mana "等" 指数 ill 察用具 B 】 4 I I A PROVED THE PERSONAL PROPERTY in 近年来,被动投资驶入"快车道" 指数类产品选择也日益丰富 而在众多指基中,有一类自带buff的存在 它既能紧跟市场的β收益 又力争创造超越指数的α收益 那就是一 】 BANGER 起突袭 或言 指数增强基金到底"强"在哪? "增强版"指数投资工具 假动 | 纯粹跟踪指数,为投资者把握市场的β收益。 在跟踪指数的基础上,通过一定策略进行增强 投资,力求超越指数创造α收益。 性品效用回族复 以跟踪沪深300、中证500、中证1000的指数增 强基金来看,近1年、3年、5年平均收益率均跑 赢了各自的跟踪标的指数,为投资者创造了可持 续的α收益,展现出良好的"超"能力。 沪深300指数增强基金业绩表现 量化模型选股,基于大数据分析科学选股 作为业内较早布局指数投资领域的基金公司之 建信基金在指数增强方面也持续发力,在 团队实力、模型搭建、产品业绩上优势显现。 HE BEATH THE SHINE HY 23.53% 25% ...